Hmnc brain health and spruce biosciences announce first patient dosed in phase 2 tamarind trial for major depressive disorder

Study initiation marks key milestone in advancing precision psychiatry treatment for major depressive disorder topline results anticipated in the first half of 2026 munich, germany and south san francisco, calif., july 22, 2025 (globe newswire) -- hmnc brain health (“hmnc”), a global precision psychiatry biopharmaceutical company, in collaboration with spruce biosciences, inc. (otcqb: sprb) (“spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that the first patient has been dosed in the phase 2 clinical trial called “tildacerfont as antidepressant medication and relief in depression” (tamarind).
SPRB Ratings Summary
SPRB Quant Ranking